Yamamoto, T.; Satoi, S.; Yamaki, S.; Hashimoto, D.; Ishida, M.; Ikeura, T.; Hirooka, S.; Matsui, Y.; Boku, S.; Nakayama, S.;
et al. Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Cancers 2022, 14, 1354.
https://doi.org/10.3390/cancers14051354
AMA Style
Yamamoto T, Satoi S, Yamaki S, Hashimoto D, Ishida M, Ikeura T, Hirooka S, Matsui Y, Boku S, Nakayama S,
et al. Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Cancers. 2022; 14(5):1354.
https://doi.org/10.3390/cancers14051354
Chicago/Turabian Style
Yamamoto, Tomohisa, Sohei Satoi, So Yamaki, Daisuke Hashimoto, Mitsuaki Ishida, Tsukasa Ikeura, Satoshi Hirooka, Yuki Matsui, Shogen Boku, Shinji Nakayama,
and et al. 2022. "Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit" Cancers 14, no. 5: 1354.
https://doi.org/10.3390/cancers14051354
APA Style
Yamamoto, T., Satoi, S., Yamaki, S., Hashimoto, D., Ishida, M., Ikeura, T., Hirooka, S., Matsui, Y., Boku, S., Nakayama, S., Nakamaru, K., Shibata, N., Katsushima, U., & Sekimoto, M.
(2022). Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Cancers, 14(5), 1354.
https://doi.org/10.3390/cancers14051354
